证券代码：920982 证券简称：锦波生物 公告编号：2025-172 山西锦波生物医药股份有限公司 质量控制复核人时斌先生近三年不存在违反《中国注册会计师职业道德守 则》对独立性要求的情形，最近三年内未曾因执业行为受到过刑事处罚、行政 处罚、行政监管措施和自律处分。 山西锦波生物医药股份有限公司（以下简称"公司"）分别于 2025 年 4 月 19 日、2025 年 5 月 21 日召开第四届董事会第八次会议、2024 年年度股东会， 审议通过了《关于聘任中汇会计师事务所（特殊普通合伙）为公司 2025 年度审 计机构的议案》，同意续聘中汇会计师事务所（特殊普通合伙）（以下简称"中 汇"）为公司 2025 年度审计机构，具体内容请详见公司于 2025 年 4 月 21 日在 北京证券交易所官网（https://www.bse.cn）披露的《拟续聘 2025 年度会计师 事务所公告》（2025-029）。 近日，公司收到中汇出具的《关于变更质量控制复核人的告知函》。 一、本次质量控制复核人变更的基本情况 中汇作为公司 2025 年度审计机构，原指派陆加龙先生为质量控制复核人， 为公司提供 2025 年度财务报 ...

山西锦波生物医药股份有限公司（以下简称"公司"）于 2025 年 10 月 27 日 召开第四届董事会第十七次会议，审议通过了《关于改选董事会相关专门委员 会委员的议案》，现将具体情况公告如下： 一、基本情况 鉴于公司董事人员发生变动，为保证董事会专门委员会顺利开展工作，根 据《公司法》等相关法律法规及《公司章程》的规定，结合董事会专门委员会 的职能职责、各位董事的行业背景及自身业务专长，公司拟对部分董事会专门 委员会委员进行改选，改选后各专门委员会的任期自本次董事会审议通过之日 起至第四届董事会届满之日止。 证券代码：920982 证券简称：锦波生物 公告编号：2025-171 山西锦波生物医药股份有限公司 关于改选部分董事会专门委员会委员的公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别 及连带法律责任。 三、上述改选对公司的影响 本次对部分董事会专门委员会委员的改选符合相关法律法规、《公司章程》 及《董事会审计委员会工作细则》的有关规定，符合公司治理要求，不会对公 司经营产生不利影响。 四、备查文件 《山西锦波 ...

证券代码：920982 证券简称：锦波生物 公告编号：2025-169 （一）会议召开情况 1.会议召开时间：2025 年 10 月 27 日 2.会议召开地点：公司三楼会议室 3.会议召开方式：现场加通讯 4.发出董事会会议通知的时间和方式：2025 年 10 月 25 日以邮件方式发出 5.会议主持人：董事长杨霞女士 6.会议列席人员：薛芳琴、兰小宾 山西锦波生物医药股份有限公司 第四届董事会第十七次会议决议公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、会议召开和出席情况 7.召开情况合法合规的说明： 本次会议的召集、召开、审议过程符合《中华人民共和国公司法》等有关法 律、行政法规、部门规章、规范性文件及《公司章程》的规定。 （二）会议出席情况 会议应出席董事 9 人，出席和授权出席董事 9 人。 董事陈镔、王玲玲、阎丽明、梁桐栋、邓泽林因出差或外地办公以通讯方式 参与表决。 二、议案审议情况 （一）审议通过《关于公司<2025 年第三季度报告>的议案》 1.议案内容： 根据《公司法》《 ...

Group 1 - The medical beauty sector experienced a decline of 0.14% on October 29, with Ai Meike leading the drop [1] - The Shanghai Composite Index closed at 4016.33, up 0.7%, while the Shenzhen Component Index closed at 13691.38, up 1.95% [1] - Key stocks in the medical beauty sector showed varied performance, with Jinbo Biological rising by 7.46% and Ai Meike falling by 1.97% [1] Group 2 - The medical beauty sector saw a net outflow of 23.498 million yuan from main funds, while retail investors had a net inflow of 39.3117 million yuan [1] - Specific stock fund flows indicated that Huaxi Biological had a main fund inflow of 8.119 million yuan, while Ai Meike experienced a significant outflow of 29.5668 million yuan [2] - The overall trend showed that retail investors were more active in the sector, with a net inflow across several stocks despite the main and speculative funds pulling back [2]

Core Viewpoint - Jinbo Biological (920982) experienced a block trade on October 28, with a transaction volume of 10,800 shares and a transaction amount of 2.2324 million yuan, at a price of 206.00 yuan, which represents a discount of 16.21% compared to the closing price of the day [2] Group 1: Block Trade Details - The block trade involved a total volume of 10,800 shares and a total transaction amount of 2.2324 million yuan [2] - The transaction price was 206.00 yuan, reflecting a discount of 16.21% relative to the closing price of the day [2] - The buyer was from Guojin Securities Co., Ltd. Shanghai Jing'an District Nanjing West Road Securities Business Department, while the seller was from Guojin Securities Co., Ltd. Shenzhen Branch [2] Group 2: Recent Trading Activity - In the past month, Jinbo Biological has recorded a total of 3 block trades, with a cumulative transaction amount of 7.2333 million yuan [2] - The closing price of Jinbo Biological on the day of the block trade was 245.86 yuan, which represents a decline of 2.05%, with a turnover rate of 2.21% and a total transaction amount of 299 million yuan [2] - Over the last 5 days, the stock has seen a cumulative decline of 6.83% [2] Group 3: Company Background - Shanxi Jinbo Biological Pharmaceutical Co., Ltd. was established on March 28, 2008, with a registered capital of 1,150.6534 million yuan [2]

Core Viewpoint - The medical beauty sector experienced a decline of 1.44% on October 28, with Jinbo Biological leading the drop. The Shanghai Composite Index closed at 3988.22, down 0.22%, while the Shenzhen Component Index closed at 13430.1, down 0.44% [1]. Group 1: Market Performance - The medical beauty sector's individual stock performance showed the following results: - Huaxi Biological closed at 52.72, down 1.03% with a trading volume of 18,000 shares and a transaction value of 95.6261 million yuan [1]. - *ST Meigu closed at 3.56, down 1.39% with a trading volume of 130,900 shares and a transaction value of 47.2460 million yuan [1]. - Aimeike closed at 163.54, down 1.74% with a trading volume of 32,100 shares and a transaction value of 529 million yuan [1]. - Jinbo Biological closed at 245.86, down 2.05% with a trading volume of 12,100 shares and a transaction value of 299 million yuan [1]. Group 2: Capital Flow - On the same day, the medical beauty sector saw a net outflow of 35.3969 million yuan from main funds, a net outflow of 24.4121 million yuan from speculative funds, and a net inflow of 59.809 million yuan from retail investors [2].

Core Insights - A block trade of 15,900 shares of Jinbo Biological (920982) occurred on October 27, with a transaction value of 3.9909 million yuan at a price of 251.00 yuan per share [1] - The buyer was Huatai Securities Co., Ltd. Kunshan Heilongjiang North Road Securities Business Department, and the seller was Guojin Securities Co., Ltd. Shenzhen Branch [1] Trading Activity - In the past month, Jinbo Biological has recorded a total of 2 block trades, amounting to a cumulative transaction value of 5.0009 million yuan [1] - The closing price of Jinbo Biological on the day of the block trade was 251.00 yuan, reflecting a decrease of 2.15%, with a daily turnover rate of 2.12% and a total trading volume of 293 million yuan [1] - Over the last five days, the stock has seen a cumulative decline of 3.83% [1] Company Background - Shanxi Jinbo Biological Pharmaceutical Co., Ltd. was established on March 28, 2008, with a registered capital of 1,150.6534 million yuan [1]

Core Insights - The recombinant collagen injection material market is seeing new entrants, with Juzi Bio (2367.HK) receiving approval for its recombinant type I collagen product for facial dermal filling, potentially disrupting the dominance of Jinbo Bio (920982.BJ) [1][2] Company Developments - Juzi Bio's product is composed of recombinant type I collagen, specifically a sequence of 753 amino acids, which does not have a triple helix structure, and is aimed at correcting dynamic facial wrinkles [1][2] - Jinbo Bio previously held a monopoly in the recombinant collagen injection market, with projected revenues of 1.443 billion yuan for 2024, reflecting over 80% year-on-year growth [2] Market Dynamics - The materials used by Juzi Bio and Jinbo Bio differ, with Juzi's focusing on type I collagen for structural support, while Jinbo's core material is type III collagen, which is responsible for elasticity [3] - Both companies have received approval for similar indications related to facial dermal filling, indicating that competition in the market is likely to intensify as more products gain regulatory approval [3]

Core Insights - The collagen market is experiencing significant growth driven by increasing consumer focus on efficacy and ingredients, with two main growth drivers: professional skin care and aesthetic injection applications [1][3] - The collagen market in China is projected to exceed 16 billion yuan at the raw material level and approach 270 billion yuan at the retail level by 2030 [1] - The industry is currently in a phase of policy refinement, accelerated technological iteration, and tight collaboration across the supply chain [1] Industry Structure - The collagen industry has a high degree of integration between raw material supply and end product manufacturing, with upstream suppliers, midstream manufacturers of recombinant collagen, and downstream sales channels [2] - The market is characterized by significant growth potential, high technological barriers, and intense competition [2] End-User Applications - The demand for professional skin care products that combine medical safety and cosmetic efficacy is rapidly increasing, particularly in the aesthetic medicine sector [3] - Applications of collagen products are expanding from traditional moisturizing and nourishing functions to include core roles in aesthetic injection materials [3] Recommended Companies - Companies to watch include: Giant Bio (02367), Jinbo Bio (920982.BJ), Marubi Bio (603983.SH), Huaxi Bio (688363.SH), Fulejia (301371.SZ), Novozymes (688105.SH), Baipusais (301080.SZ), and Betaini (300957.SZ) [4]

Group 1 - The medical beauty sector experienced a decline of 0.12% on October 23, with Jinbo Biological leading the drop [1] - The Shanghai Composite Index closed at 3922.41, up 0.22%, while the Shenzhen Component Index closed at 13025.45, also up 0.22% [1] - Key stocks in the medical beauty sector showed mixed performance, with Aimeike rising by 0.64% and Jinbo Biological falling by 2.84% [1] Group 2 - The net outflow of main funds in the medical beauty sector was 32.09 million yuan, while retail funds saw a net inflow of 10.22 million yuan [1] - Specific stock fund flows indicated that *ST Meigu experienced a main fund outflow of 6.29 million yuan, while retail funds had a net inflow of 6.18 million yuan [2] - Huaxi Biological also faced a main fund outflow of 10.03 million yuan, with retail funds showing a net inflow of 4.67 million yuan [2]